Subcutaneous defibrillators for dialysis patients.
Tushar J VachharajaniLoay SalmanEric J CostanzoSushil K MehandruMayurkumar PatelDawn M CalderonRoy O MathewMandeep S SidhuArif AsifPublished in: Hemodialysis international. International Symposium on Home Hemodialysis (2017)
Defibrillation can be successfully provided by the subcutaneous implantable cardioverter defibrillator (ICD) without the leads. In contrast, traditional ICDs require leads that can cause central venous stenosis, lead-induced endocarditis, and carry the risk of tricuspid regurgitation by valve adhesion, perforation, coaptation interference, or entanglement. Central venous stenosis, infection, and tricuspid regurgitation are all critically important considerations in hemodialysis patients. Recent reports are supporting the use of subcutaneous ICDs in renal patients maintained on long-term hemodialysis. This article provides the risks associated with leads of traditional defibrillators and raises awareness of the subcutaneous ICD and their benefits for hemodialysis patients.
Keyphrases
- end stage renal disease
- chronic kidney disease
- aortic valve
- peritoneal dialysis
- ejection fraction
- newly diagnosed
- mitral valve
- prognostic factors
- heart failure
- transcatheter aortic valve replacement
- escherichia coli
- patient reported outcomes
- computed tomography
- pseudomonas aeruginosa
- staphylococcus aureus
- coronary artery disease
- patient reported
- cardiac resynchronization therapy
- drug induced
- contrast enhanced